Advisory: Alert from Equity-Insider.com was published in error and has been withdrawn
An alert on cancer drug developers was inadvertently filed off a commentary by Equity-Insider.com and tagged to Immunome IMNM.O, Prelude Therapeutics PRLD.O, Context Therapeutics CNTX.O, Relay Therapeutics RLAY.O and Oncolytics ONCY.O. The alert has been withdrawn and there will be no substitute. STORY_NUMBER: nTUA1LWBBS STORY_DATE: 16/12/2025 STORY_TIME: 05:18:00 PM GMT ((bangalore.newsroom@thomsonreuters.com))
Recent news on Oncolytics Biotech
See all newsBrief: Oncolytics Biotech Announces Clinical Supply Agreement To Evaluate Pelareorep In Combination With Loqtorzi In Squamous Cell Anal Carcinoma
Brief: Oncolytics Says Pelareorep Shows Durable Survival Benefit in Anal Cancer
Brief: Oncolytics Biotech Expects Final Cohort 4 Results Of Goblet Study In Q4 2026
Brief: Oncolytics Biotech® Secures Patent Protection To Late 2040S And Provides Intellectual Property Portfolio Update
Brief: Oncolytics Biotech® Aligns With FDA On Registrational Path For Second-Line Ras-Mutant Mss Colorectal Cancer